Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06155942
Other study ID # RCAPHM22_0291
Secondary ID ID-RCB
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 15, 2024
Est. completion date January 15, 2028

Study information

Verified date November 2023
Source Assistance Publique Hopitaux De Marseille
Contact Stephan Grimaldi, MD
Phone 0491385266
Email stephan.grimaldi@ap-hm.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Parkinson's disease (PD) is the most common degenerative Parkinson's syndrome and is linked, among other things, to the excessive accumulation of an abnormally aggregating protein, alpha-synuclein. Progressive Supranuclear Palsy (PSP) is another Parkinson's syndrome, linked, among other things, to the abnormal accumulation of the protein Tau, and expressed clinically by falls, early cognitive impairment and oculomotor disorders, not present in PD. The onset of these disorders is so gradual that differential diagnosis between the two diseases is only possible at a late stage, on average 3 to 5 years after the onset of symptoms. To date, there is a lack of validated imaging biomarkers for diagnosing and monitoring PD and PSP. There is therefore an urgent need for the development of robust biomarkers capable of detecting neurodegeneration at an early stage, in order to aid differential diagnosis as soon as symptoms appear, and to potentially enable these patients to be included in specific therapeutic trials (as these diseases are pathophysiologically different) with potential neuroprotective effects. The development of cutting-edge technologies such as 7T MRI, combined with optimized image processing methods, now enable non-invasive in vivo exploration and analysis of these small structures in terms of ion homeostasis (sodium), microstructure (volumetry, amount of iron and neuromelanin) and connectivity.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 63
Est. completion date January 15, 2028
Est. primary completion date January 15, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 80 Years
Eligibility For Parkinson Disease: Inclusion Criteria: 1. Patients aged between 40 and 80 2. Fulfilling the diagnostic criteria for MPI (Postuma et al., 2015) 3. First motor symptom (rigidity, akinesia, tremor) less than 36 months ago 4. Patient entitled to or affiliated with a social security scheme 5. Patients who understood, completed and signed the consent form for study participation. Exclusion Criteria: 1. Patient with a neurological disease of the central nervous system other than those studied (including history of stroke, repeated head trauma, documented encephalitis). In case of doubt, this criterion will be left to the discretion of the principal investigator, who is a neurologist. 2. Contraindications to 7T MRI: presence of an ocular metallic foreign body (accidental shrapnel or other), pacemaker (cardiac simulator) or neurostimulator (pain treatment), cochlear implants or any implanted electronic medical equipment in general, metallic heart valve, vascular clips implanted on a cranial aneurysm. 3. Claustrophobia or any other condition preventing full MRI. 4. Montreal Cognitive Assessment (MOCA) test < 25/30 5. Pregnant or breast-feeding woman or protected person (under guardianship, curatorship, deprived of liberty). For Progressive Supra-nuclear Palsy: Inclusion criteria: 1. Patients aged 40 to 80 2. Fulfilling the diagnostic criteria for soPSP (Höglinger et al., 2017) : 3. First motor symptom (rigidity, akinesia, tremor) or falls or cognitive impairment (frontal syndrome or language disorder or cortico-basal syndrome) occurring less than 36 months ago 4. Patients benefiting from or affiliated to a social security scheme 5. Patients who have understood, completed and signed the study participation consent form Exclusion criteria: 1. Patient with a neurological disease of the central nervous system other than those studied (including history of stroke, repeated head trauma, documented encephalitis). In case of doubt, this criterion will be left to the discretion of the principal investigator, who is a neurologist. 2. Contraindications to 7T MRI: presence of an ocular metallic foreign body (accidental shrapnel or other), pacemaker (cardiac simulator) or neurostimulator (pain treatment), cochlear implants or any implanted electronic medical equipment in general, metallic heart valve, vascular clips implanted on a cranial aneurysm. 3. Claustrophobia or any other condition preventing MRI. 4. Pregnant or breast-feeding woman or protected person (under guardianship, curatorship, deprived of liberty). For Control group: Inclusion criteria: 1. Subjects aged between 40 and 80 2. Subjects benefiting from or affiliated with a social security plan 3. Subjects who have understood, completed and signed the study participation consent form Exclusion criteria: 1. Subjects with a known history of neurological disease of the central nervous system (e.g. Parkinson's disease, Alzheimer's, stroke, brain tumor, multiple sclerosis, amyotrophic lateral sclerosis, repeated head trauma, documented encephalitis, etc.). In case of doubt, this criterion will be left to the discretion of the principal investigator, who is a neurologist. 2. Contraindications to 7T MRI: presence of an ocular metallic foreign body (accidental shrapnel or other), pacemaker (cardiac simulator) or neurostimulator (pain treatment), cochlear implants or any implanted electronic medical equipment in general, metallic heart valve, vascular clips implanted on a cranial aneurysm. 3. Claustrophobia or any other condition preventing MRI. 4. Pregnant or breast-feeding women or protected persons (under guardianship, curatorship, deprived of liberty).

Study Design


Intervention

Procedure:
7 Tesla MRI
Patients will have a 7T MRI and questionnaires

Locations

Country Name City State
France Ch Pays D'Aix Aix-en-Provence
France Hôpital Privé La Casamance - Service de Neurologie Aubagne
France Centre Hospitalier Avignon - Service de Neurologie Avignon
France CENTRE HOSPITALIER UNIVERSITAIRE NICE - Service de Neurologie Nice
France CENTRE HOSPITALIER NIMES - Service de Neurologie Nimes
France CENTRE HOSPITALIER SAINTE MUSSE - Toulon Toulon

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sodium accumulation between Parkinson disease patients and Progressive Supranuclear Palsy Comparison of intracerebral sodium accumulation measured by very high-field (7T) cerebral MRI between subjects with Idiopathic Parkinson's Disease and subjects with early-stage Progressive Supra-Nuclear Palsy Between month 0 and month 3 after inclusion
Secondary Sodium accumulation between Parkinson disease patients (MPI) and control subjects Comparison of intracerebral sodium accumulation between subjects with early-stage Parkinson's Disease (PD) and control subjects. Between month 0 and month 3 after inclusion
Secondary Sodium accumulation between Progressive Supra-nuclear patients (soPSP) and control subjects Comparison of intracerebral sodium accumulation between subjects with soPSP and control subjects. Between month 0 and month 3 after inclusion
Secondary Brain atrophy between MPI and soPSP patients 3D mapping of brain atrophy differences measured in Voxel Based Morphometry (VBM), value in cm3 Between month 0 and month 3 after inclusion
Secondary Brain atrophy between MPI and control group 3D mapping of brain atrophy differences measured in Voxel Based Morphometry (VBM), value in cm3 Between month 0 and month 3 after inclusion
Secondary Brain atrophy between soPSP and control group 3D mapping of brain atrophy differences measured in Voxel Based Morphometry (VBM), value in cm3 Between month 0 and month 3 after inclusion
Secondary Iron accumulation between soPSP and control group 3D mapping of iron accumulation differences measured by Quantitative Susceptibility Mapping (QSM), values in ppm Between month 0 and month 3 after inclusion
Secondary Iron accumulation between MPI and soPSP patients 3D mapping of iron accumulation differences measured by Quantitative Susceptibility Mapping (QSM), values in ppm Between month 0 and month 3 after inclusion
Secondary Iron accumulation between soPSP patients and control group 3D mapping of iron accumulation differences measured by Quantitative Susceptibility Mapping (QSM), values in ppm Between month 0 and month 3 after inclusion
Secondary Accumulation of neuromelanin between MPI and soPSP patients 3D mapping of neuromelanin differences (signal/MT ratio) Between month 0 and month 3 after inclusion
Secondary Accumulation of neuromelanin between MPI patients and control group 3D mapping of neuromelanin differences (signal/MT ratio) Between month 0 and month 3 after inclusion
Secondary Accumulation of neuromelanin between soPSP patients and control group 3D mapping of neuromelanin differences (signal/MT ratio) Between month 0 and month 3 after inclusion
Secondary Movement of water molecules between MPI and soPSP patients 3D mapping of differences in mean diffusivity (DM), values in mm2/s Between month 0 and month 3 after inclusion
Secondary Movement of water molecules between MPI patients and control group 3D mapping of differences in mean diffusivity (DM), values in mm2/s Between month 0 and month 3 after inclusion
Secondary Movement of water molecules between soPSP patients and control group 3D mapping of differences in mean diffusivity (DM), values in mm2/s Between month 0 and month 3 after inclusion
Secondary Structural connectivity between MPI and soPSP patients 3D mapping of anisotropy fraction (AF) differences, values between 0 and 1 Between month 0 and month 3 after inclusion
Secondary Structural connectivity between soPSP patients and control group 3D mapping of anisotropy fraction (AF) differences, values between 0 and 1 Between month 0 and month 3 after inclusion
Secondary Structural connectivity between MPI patients and control group 3D mapping of anisotropy fraction (AF) differences, values between 0 and 1 Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and age Correlation between sodium concentration (mmol/L) and age Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and sex Correlation between sodium concentration (mmol/L) and sex Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and laterality Correlation between sodium concentration (mmol/L) and laterality Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and sex Measure by Voxel Based Morphometry (VBM) in cm3 and sex Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and age Measure by Voxel Based Morphometry (VBM) in cm3 and age Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and laterality Measure by Voxel Based Morphometry (VBM) in cm3 and laterality Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and age Measure by Quantitative Susceptibility Mapping (QSM) in ppm and age Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and sex Measure by Quantitative Susceptibility Mapping (QSM) in ppm and sex Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and laterality Measure by Quantitative Susceptibility Mapping (QSM) in ppm and laterality Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and age Correlation between ratio of signal/MT and age Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and sex Correlation between ratio of signal/MT and sex Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and laterality Correlation between ratio of signal/MT and laterality Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and age Correlation between anisotropy fraction (AF) and age Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and sex Correlation between anisotropy fraction (AF) and sex Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and laterality Correlation between anisotropy fraction (AF) and laterality Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and duration of disease progression Correlation between anisotropy fraction (AF) and duration of the disease Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and duration of disease progression Correlation between ratio of signal/MT and duration of the disease Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and duration of disease progression Measure by Quantitative Susceptibility Mapping (QSM) in ppm and duration of the disease Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and duration of disease progression Measure by Voxel Based Morphometry (VBM) in cm3 and duration of disease progression Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and duration of disease progression Correlation between sodium concentration (mmol/L) and duration of disease Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and sense of smell Correlation between sodium concentration (mmol/L) and sense of smell (questionnaire) Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and sense of smell Measure by Voxel Based Morphometry (VBM) in cm3 and sense of smell (questionnaire) Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and sense of smell Measure by Quantitative Susceptibility Mapping (QSM) in ppm and sense of smell (questionnaire) Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and sense of smell Correlation between ratio of signal/MT and sense of smell (questionnaire) Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and sense of smell Correlation between anisotropy fraction (AF) and sense of smell (questionnaire) Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and severity of disease Unified Parkinson's Disease Rating Scale (UPDRS), 0 to 199, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and quality of life Schwab & England score, 0 to 100%, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and quality of life Schwab & England score, 0 to 100%, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and quality of life Schwab & England score, 0 to 100%, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and quality of life Schwab & England score, 0 to 100%, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and quality of life Correlation between Schwab & England score (Schwab & England score, 0 to 100%, 0 means better outcome) and sodium concentration (mmol/L) Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and severity of disease Unified Parkinson's Disease Rating Scale (UPDRS), 0 to 199, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and severity of disease Unified Parkinson's Disease Rating Scale (UPDRS), 0 to 199, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and severity of disease Unified Parkinson's Disease Rating Scale (UPDRS), 0 to 199, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and Hospital Anxiety and Depression HAD Echelle (Hospital Anxiety and Depression), 0 to 3, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and Hospital Anxiety and Depression HAD Echelle (Hospital Anxiety and Depression), 0 to 3, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and Hospital Anxiety and Depression HAD Echelle (Hospital Anxiety and Depression), 0 to 3, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and Hospital Anxiety and Depression HAD Echelle (Hospital Anxiety and Depression), 0 to 3, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and Hospital Anxiety and Depression HAD Echelle (Hospital Anxiety and Depression), 0 to 3, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and Sleep Behavior Disorder REM Sleep Behavior Disorder Screening Questionnaire, 0 to 13, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and Sleep Behavior Disorder REM Sleep Behavior Disorder Screening Questionnaire, 0 to 13, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and Sleep Behavior Disorder REM Sleep Behavior Disorder Screening Questionnaire, 0 to 13, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and Sleep Behavior Disorder REM Sleep Behavior Disorder Screening Questionnaire, 0 to 13, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and Sleep Behavior Disorder REM Sleep Behavior Disorder Screening Questionnaire, 0 to 13, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and motivation scale Starkstein motivation scale, 0 to 42, 0 means worse outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and motivation scale Starkstein motivation scale, 0 to 42, 0 means worse outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and motivation scale Starkstein motivation scale, 0 to 42, 0 means worse outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and motivation scale Starkstein motivation scale, 0 to 42, 0 means worse outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and motivation scale Starkstein motivation scale, 0 to 42, 0 means worse outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and non-motor fluctuations Number of non-motor fluctuations Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and non-motor fluctuations Number of non-motor fluctuations Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and non-motor fluctuations Number of non-motor fluctuations Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and non-motor fluctuations Number of non-motor fluctuations Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and non-motor fluctuations Number of non-motor fluctuations Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and cognitives functions Score Montreal Cognitive Assessment (MoCA), 0 to 30, 0 means worse outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and cognitives functions Score Montreal Cognitive Assessment (MoCA), 0 to 30, 0 means worse outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and cognitives functions Score Montreal Cognitive Assessment (MoCA), 0 to 30, 0 means worse outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and cognitives functions Score Montreal Cognitive Assessment (MoCA), 0 to 30, 0 means worse outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and cognitives functions Score Montreal Cognitive Assessment (MoCA), 0 to 30, 0 means worse outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and quality of life Parkinson's Disease Questionnaire (PDQ 39), 0 to 156, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and quality of life Parkinson's Disease Questionnaire (PDQ 39), 0 to 156, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and quality of life Parkinson's Disease Questionnaire (PDQ 39), 0 to 156, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and quality of life Parkinson's Disease Questionnaire (PDQ 39), 0 to 156, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and quality of life Parkinson's Disease Questionnaire (PDQ 39), 0 to 156, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and hypotension Blood pressure test for orthostatic hypotension Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and hypotension Blood pressure test for orthostatic hypotension Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and hypotension Blood pressure test for orthostatic hypotension Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and hypotension Blood pressure test for orthostatic hypotension Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and hypotension Blood pressure test for orthostatic hypotension Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between structural connectivity and hallucinations Miami Questionnaire, 0 to 70, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between accumulation of neuromelanin and hallucinations Miami Questionnaire, 0 to 70, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between iron accumulation and hallucinations Miami Questionnaire, 0 to 70, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between brain atrophy and hallucinations Miami Questionnaire, 0 to 70, 0 means better outcome Between month 0 and month 3 after inclusion
Secondary Measurement of the dependency between sodium accumulation and hallucinations Miami Questionnaire, 0 to 70, 0 means better outcome Between month 0 and month 3 after inclusion
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A